Skip to main content
Retour
Watch Compare

Acurx Pharmaceuticals, Inc.

Qualité des données : 83%
ACXP
NASDAQ Manufacturing Chemicals
2,61 €
▼ 0,08 € (-2,97%)
Cap. Boursière: 7,66 M
Prix
2,68 €
Cap. Boursière
7,66 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -6,79 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-221,19%
En dessous de la moyenne du secteur (-53,58%)
ROIC-178,80%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-0,96 | -1,19
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio2,11
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E -1,0 -1,5
P/B 2,1 1,6
ROE % -221,2 -53,6
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

3 analystes
Buy
Actuel
2,61 €
+551.3%
Objectif
17,00 €
10,00 €
10,00 €
31,00 €
Prévisions
P/E Prévisionnel -1,19
BPA Prévisionnel -2,20 €
CA Est. 0,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -2,20 €
-2,55 € – -1,85 €
 0,0 2
FY2026 -2,39 €
-2,68 € – -2,10 €
 0,0 2

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -1,00 € -0,31 € +68,8%
Q32025 -1,49 € -1,23 € +17,2%
Q22025 -2,10 € -1,89 € +10,0%
Q12025 -2,80 € -2,20 € +21,4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7,97 M
ROE -221,19% ROA -130,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,79 M
ROIC -178,80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 3,64 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,96 Forward P/E -1,19
P/B Ratio 2,11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -88,65%
Market Cap 7,66 M Enterprise Value 7,66 M
Per Share
EPS (Diluted TTM) -5,32 Revenue / Share N/A
FCF / Share -2,38 OCF / Share -2,38
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85,20%
SBC-Adj. FCF -8,09 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7,97 M -14,10 M -14,58 M -12,09 M -12,75 M
EPS (Diluted) -5,32 -0,87 -1,15 -1,12 -1,49
Gross Profit — — — — —
Operating Income -8,09 M — — — —
EBITDA — — — — —
R&D Expenses 1,83 M 5,40 M 6,04 M 4,75 M 2,03 M
SG&A Expenses — — — — 208 270,0
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,69 M 3,86 M 7,71 M 9,38 M 13,25 M
Total Liabilities 2,42 M 3,24 M 3,04 M 2,06 M 843 909,0
Shareholders' Equity 5,27 M 615 121,0 4,67 M 7,32 M —
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets — — — — —
Current Liabilities 2,42 M 3,24 M 3,04 M 2,06 M 843 909,0